Stocks & ETFs Screener: 200+ results (Biotechnology)
| Symbol | Industry | Market Cap | Fund. Score | Div. Score | Tech. Score | P/E | Return 12m vs S&P 500 |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie |
Biotechnology
Biologics, Immunology, Oncology |
402B | 48.1% | 73.7% | 82.6% | 172 | 11.8% |
| AMGN Amgen |
Biotechnology
Biologics, Oncology, Osteoporosis |
186B | 82.0% | 67.7% | 56.1% | 26.7 | 9.93% |
| GILD Gilead Sciences |
Biotechnology
HIV/Aids Therapeutics, Hepatitis |
158B | 83.2% | 65.3% | 84.1% | 19.7 | 18.8% |
| VRTX Vertex |
Biotechnology
Cystic Fibrosis Treatments, Gene |
109B | 87.0% | - | 22.7% | 30.0 | -18.6% |
| REGN Regeneron |
Biotechnology
Eye, Dermatology, Asthma, Cancer |
83.2B | 75.5% | 14.9% | -7.08% | 18.8 | -14.4% |
| ALNY Alnylam |
Biotechnology
ONPATTRO, AMVUTTRA, GIVLAARI |
57.4B | 61.7% | - | 87.2% | - | 60.8% |
| ARGX argenx |
Biotechnology
Antibody,Autoimmune,Therapy,FcRn,Ig.. |
57.1B | 71.1% | - | 81.7% | 39.2 | 29.7% |
| INSM Insmed |
Biotechnology
Inhaled Antibiotic, DPP1 |
44.3B | 32.6% | - | 87.5% | - | 150% |
| HLN Haleon |
Biotechnology
Toothpaste, Vitamins, Pain-Relief |
44.0B | 60.1% | 53.3% | 37.6% | 22.3 | -10.9% |
| ONC BeiGene |
Biotechnology
BTK-Inhibitor, Anti-PD-1 |
38.7B | 64.5% | - | 64.4% | 659 | 40.4% |
| NTRA Natera |
Biotechnology
Prenatal Screening, Carrier |
32.3B | 47.9% | - | 71.1% | - | 21.9% |
| BIIB Biogen |
Biotechnology
Multiple Sclerosis Therapies |
25.9B | 66.7% | - | -33.4% | 16.1 | -4.0% |
| 22UA BioNTech SE |
Biotechnology
Cancer Vaccines, mRNA Therapies |
23.9B | 17.5% | 1.0% | -68.4% | - | -35.7% |
| BNTX BioNTech SE |
Biotechnology
Oncology Vaccines,Checkpoint |
23.4B | 12.8% | 1.0% | -55.8% | - | -28.2% |
| UTHR United Therapeutics |
Biotechnology
Treprostinil, Treprostinil |
22.0B | 92.2% | - | 66.5% | 18.1 | 12.1% |
| INCY Incyte |
Biotechnology
JAKAFI, MONJUVI, PEMAZYRE |
20.0B | 90.1% | - | 33.2% | 17.3 | 21.2% |
| EXAS EXACT Sciences |
Biotechnology
Colorectal, Breast, Colon |
19.2B | 47.3% | - | 40.3% | - | 43.6% |
| GMAB Genmab AS |
Biotechnology
Antibody, Cancer, Lymphoma |
18.8B | 78.6% | - | -0.07% | 13.4 | 27.1% |
| RVMD Revolution |
Biotechnology
RAS Inhibitors, Companion |
15.0B | 24.9% | - | 66.0% | - | 27.2% |
| BIM Biomerieux |
Biotechnology
Diagnostic, Instruments, Reagents |
15.0B | 78.1% | 60.4% | 21.3% | 34.6 | -2.62% |
| ROIV Roivant Sciences |
Biotechnology
Antibody, Small-Molecule, Inhaled |
14.5B | 31.5% | - | 83.9% | - | 40.9% |
| NBIX Neurocrine |
Biotechnology
Movement, Endocrine |
14.1B | 85.8% | - | 45.4% | 33.6 | 5.99% |
| BBIO BridgeBio Pharma |
Biotechnology
ATTR Medication, FGFR Inhibitor |
13.8B | 48.9% | - | 83.1% | - | 135% |
| IONS Ionis |
Biotechnology
Triglyceride, Amyloidosis, SMA |
13.4B | 19.8% | 0.21% | 73.4% | - | 97.1% |
| MDGL Madrigal |
Biotechnology
Rezdiffra, Liver Therapy, MASH |
13.4B | 55.5% | - | 84.1% | - | 57.4% |
| ASND Ascendis Pharma AS |
Biotechnology
Growth Hormone |
12.9B | 35.9% | - | 75.4% | - | 32.5% |
| SMMT Summit Therapeutics |
Biotechnology
Antibody, Immunotherapy, Oncology |
12.3B | 43.1% | - | 49.8% | - | -18.4% |
| ERF Eurofins |
Biotechnology
Testing, Laboratory, Services |
12.1B | 70.1% | 2.81% | 15.2% | 26.0 | 12.5% |
| EXEL Exelixis |
Biotechnology
Cabozantinib, Cobimetinib |
11.7B | 93.0% | - | 80.9% | 18.3 | 6.81% |
| RNA Avidity Biosciences |
Biotechnology
Antibody-Oligonucleotide |
10.7B | 33.3% | - | 82.0% | - | 51.6% |
| BMRN Biomarin |
Biotechnology
Enzyme replacement therapy |
10.6B | 86.0% | - | -72.1% | 20.5 | -27.5% |
| MRNA Moderna |
Biotechnology
Respiratory Vaccines, Latent |
9.44B | 22.3% | - | -85.9% | - | -52.4% |
| CYTK Cytokinetics |
Biotechnology
Cardiac Activator, Skeletal |
8.33B | 35.9% | - | 47.8% | - | 9.77% |
| HALO Halozyme |
Biotechnology
Enzyme, Cancer, Immunodeficiency |
8.26B | 92.1% | - | 47.3% | 14.8 | 19.8% |
| ABVX Abivax American |
Biotechnology
Obefazimod, Immunoregulatory |
8.19B | 38.7% | - | 77.3% | - | 1,085% |
| ABVX Abivax |
Biotechnology
Immunomodulator, Inflammatory |
8.08B | 42.5% | - | 70.4% | - | 1,033% |
| NUVL Nuvalent |
Biotechnology
ROS1 Inhibitor, ALK Inhibitor |
7.70B | 28.9% | - | 71.1% | - | -2.57% |
| GRFS Grifols |
Biotechnology
Immunoglobulin, Albumin |
7.65B | 68.4% | 40.9% | 22.9% | 13.8 | 6.17% |
| ARWR Arrowhead |
Biotechnology
Plozasiran, Olpasiran, Fazirsiran |
7.29B | 49.4% | - | 38.6% | - | 92.5% |
| CDTX Cidara Therapeutics |
Biotechnology
Antifungal, Antiviral, Oncology |
6.90B | 23.5% | - | 78.3% | - | 926% |
| RYTM Rhythm |
Biotechnology
Setmelanotide, Rare Obesity, MC4R |
6.79B | 43.0% | - | 93.6% | - | 45.8% |
| PTCT PTC Therapeutics |
Biotechnology
Translarna, Emflaza, Upstaza |
6.36B | 65.5% | - | 59.5% | 9.21 | 31.9% |
| KRYS Krystal Biotech |
Biotechnology
Gene, Therapy, Topical, Wound, Skin |
6.32B | 89.0% | - | 61.7% | 32.7 | -3.45% |
| PCVX Vaxcyte |
Biotechnology
Pneumococcal, Streptococcus |
6.25B | 27.0% | - | -12.2% | - | -57.3% |
| RGC Regencell |
Biotechnology
Traditional Chinese Medicine |
6.24B | 37.2% | - | 77.8% | - | 6,413% |
| COGT Cogent Biosciences |
Biotechnology
Kinase Inhibitor, FGFR Inhibitor |
6.10B | 49.6% | - | 66.0% | - | 260% |
| PTGX Protagonist |
Biotechnology
Peptide, Hematology, Inflammation |
5.63B | 63.9% | - | 89.7% | 136 | 71.2% |
| ACLX Arcellx |
Biotechnology
Anitocabtagene Autoleucel |
5.24B | 40.5% | - | 62.8% | - | -37.1% |
| TGTX TG Therapeutics |
Biotechnology
Anti-CD20 Antibody, BTK Inhibitor |
5.09B | 67.3% | - | 34.5% | 11.6 | -23.6% |
| LEGN Legend Biotech |
Biotechnology
CAR-T, Oncology, Myeloma |
5.08B | 29.2% | - | -55.4% | - | -46.1% |
| KYMR Kymera Therapeutics |
Biotechnology
IRAK4, STAT6, TYK2, Protein |
4.88B | 29.1% | - | 61.0% | - | 17.8% |
| CRSP Crispr Therapeutics |
Biotechnology
Gene-Edited Cell Therapy, CAR T |
4.79B | 31.3% | - | 7.60% | - | -18.2% |
| ALKS Alkermes |
Biotechnology
Schizophrenia, Bipolar, Alcohol |
4.77B | 89.7% | - | 7.91% | 14.4 | -13.7% |
| PRAX Praxis Precision |
Biotechnology
Ulixacaltamide, Vormatrigine |
4.71B | 30.8% | - | 46.2% | - | 101% |
| NAMS NewAmsterdam |
Biotechnology
Obicetrapib, Ezetimibe, CETP |
4.70B | 27.2% | - | 82.9% | - | 70.8% |
| CELC Celcuity |
Biotechnology
Cancer Test, Therapy Candidate |
4.64B | 24.8% | - | 79.0% | - | 576% |
| APGE Apogee |
Biotechnology
Monoclonal Antibody, Atopic |
4.53B | 35.0% | - | 67.3% | - | 31.1% |
| GRAL GRAIL |
Biotechnology
Cancer Screening, Diagnostic Aid |
4.29B | 40.8% | - | 91.6% | - | 355% |
| CNTA Centessa |
Biotechnology
Sleep Disorder Drug |
4.23B | 33.4% | - | 72.9% | - | 47.2% |
| BLTE Belite Bio |
Biotechnology
Oral Therapy, Stargardt |
4.21B | 32.1% | - | 88.7% | - | 106% |
| INDV Indivior Ordinary |
Biotechnology
Suboxone, Sublocade, Subutex, Opvee |
4.20B | 74.1% | 2.63% | 62.8% | 34.3 | 165% |
| ADMA ADMA Biologics |
Biotechnology
IVIG, Immune Globulin, Hepatitis |
4.10B | 85.0% | - | 46.4% | 20.0 | -14.5% |
| IMVT Immunovant |
Biotechnology
Monoclonal Antibodies, Autoimmune |
4.09B | 25.8% | - | 11.9% | - | -33.1% |
| CRNX Crinetics |
Biotechnology
Paltusotine, Atumelnant, CRN09682 |
4.07B | 21.7% | - | 44.4% | - | -31.4% |
| LGND Ligand |
Biotechnology
Infectious, Oncology, Nephrology |
4.06B | 52.1% | 0.14% | 83.3% | 90.8 | 39.1% |
| ACAD ACADIA |
Biotechnology
Parkinsons Psychosis Drug, Rett |
3.99B | 86.7% | - | 56.4% | 15.2 | 34.0% |
| VKTX Viking Therapeutics |
Biotechnology
VK2809, VK2735, VK5211, VK0214 |
3.91B | 40.5% | - | 48.2% | - | -42.5% |
| SRRK Scholar Rock |
Biotechnology
Monoclonal Antibodies, Inhibitor |
3.88B | 25.9% | - | 35.3% | - | -5.30% |
| ARQT Arcutis |
Biotechnology
Topical Cream, Topical Foam, JAK1 |
3.79B | 41.9% | - | 50.0% | - | 107% |
| MIRM Mirum |
Biotechnology
LIVMARLI, Cholbam, Chenodal |
3.55B | 48.2% | - | 92.0% | - | 32.3% |
| IRON Disc Medicine |
Biotechnology
Porphyria Drug, Anemia Drug |
3.54B | 36.4% | - | 47.1% | - | 22.3% |
| VCYT Veracyte |
Biotechnology
Thyroid, Prostate, Bladder |
3.48B | 63.3% | - | 21.8% | 116 | -8.45% |
| CGON CG Oncology |
Biotechnology
Oncolytic Immunotherapy |
3.42B | 32.2% | - | 18.4% | - | 1.20% |
| MLYS Mineralys |
Biotechnology
Phase II Inhibitor, Oral |
3.31B | 31.1% | - | 72.8% | - | 154% |
| TVTX Travere |
Biotechnology
Medication, Tablets, Enzyme |
3.24B | 27.6% | - | 40.5% | - | 52.0% |
| RARE Ultragenyx |
Biotechnology
Biologic, Gene Therapy, Antibody |
3.24B | 36.5% | - | -54.8% | - | -38.5% |
| RCUS Arcus Biosciences |
Biotechnology
HIF-2a-Inhibitor |
3.23B | 29.5% | - | -14.5% | - | 39.6% |
| KNSA Kiniksa |
Biotechnology
ARCALYST, Vixarelimab, KPL-387 |
3.22B | 66.9% | - | 93.7% | 94.5 | 60.5% |
| XENE Xenon |
Biotechnology
Kv7 Opener, Phase 3, Epilepsy |
3.18B | 29.2% | - | 17.7% | - | -10.9% |
| IDYA Ideaya Biosciences |
Biotechnology
Oncology, Kinase, Inhibitor, ADC |
3.15B | 22.9% | - | 58.4% | - | 7.40% |
| VRDN Viridian |
Biotechnology
Monoclonal Antibody, Thyroid Eye |
3.05B | 46.9% | - | 28.3% | - | 26.8% |
| FOLD Amicus Therapeutics |
Biotechnology
Galafold, Pombiliti, Opfolda, Gene |
2.95B | 52.6% | - | -29.4% | - | -14.5% |
| DYN Dyne Therapeutics |
Biotechnology
Therapeutics, Muscular Dystrophy |
2.94B | 29.6% | - | 18.6% | - | -40.3% |
| CPRX Catalyst |
Biotechnology
Firdapse, Fycompa, Ruzurgi, Agamree |
2.86B | 91.5% | - | 21.3% | 13.6 | -12.2% |
| DNLI Denali Therapeutics |
Biotechnology
RIPK1 Inhibitor, LRRK2 Inhibitor |
2.78B | 25.0% | - | -61.1% | - | -39.1% |
| NUVB Nuvation Bio |
Biotechnology
Taletrectinib, Safusidenib |
2.75B | 36.3% | - | 60.4% | - | 119% |
| APLS Apellis |
Biotechnology
Therapeutic, Complement |
2.48B | 76.8% | - | -62.1% | 54.5 | -49.0% |
| SLNO Soleno Therapeutics |
Biotechnology
Diazoxide, Choline, Tablet, Rare |
2.42B | 41.4% | - | 63.8% | - | -15.8% |
| EWTX Edgewise |
Biotechnology
Muscle Disorder Therapies |
2.40B | 29.8% | - | 15.3% | - | -36.2% |
| IBRX Immunitybio |
Biotechnology
Immunotherapy, Vaccine, Cytokine |
2.32B | 65.8% | - | -75.0% | - | -63.2% |
| NNNN Anbio |
Biotechnology
Antigen Tests, Immunoassay |
2.32B | 66.8% | - | 84.4% | 858 | 328% |
| BEAM Beam Therapeutics |
Biotechnology
Base-Editing Therapeutics, Sickle |
2.25B | 28.0% | - | -58.3% | - | -27.7% |
| SYRE Spyre Therapeutics |
Biotechnology
Monoclonal Antibodies |
2.22B | 29.1% | - | 25.2% | - | -10.1% |
| ZLAB Zai Lab |
Biotechnology
Oncology, Immunology |
2.22B | 30.9% | - | -47.0% | - | -41.5% |
| RXRX Recursion |
Biotechnology
Drug Discovery Platform |
2.17B | 30.1% | - | -72.1% | - | -50.1% |
| AUPH Aurinia |
Biotechnology
Immunosuppressant, Lupus |
2.12B | 93.8% | - | 62.5% | 28.8 | 53.0% |
| GPCR Structure |
Biotechnology
GSBR-1290, ACCG-2671, ANPA-0073 |
2.08B | 31.2% | - | 22.5% | - | -17.2% |
| ZYME Zymeworks Common |
Biotechnology
Zanidatamab, Bispecific Antibody |
2.07B | 28.9% | - | 67.7% | - | 51.5% |
| SRPT Sarepta |
Biotechnology
RNA Therapeutics, Duchenne |
2.07B | 30.3% | - | -76.4% | - | -86.0% |
| GLPG Galapagos |
Biotechnology
CAR-T, Oncology, Immunology |
2.03B | 25.3% | - | -18.0% | - | -11.0% |
| GLPG Galapagos |
Biotechnology
Medicine, Oncology, Immunology |
2.02B | 37.8% | - | 2.14% | - | -1.99% |
| VCEL Vericel Ord |
Biotechnology
Cartilage, Skin, Burn, Autologous |
2.00B | 61.7% | - | -3.95% | 152 | -43.9% |
| IMCR Immunocore Holdings |
Biotechnology
Oncology Immunotherapy |
1.99B | 41.7% | - | -3.04% | - | -2.58% |
| SION Sionna |
Biotechnology
Galicaftor, Navocaftor, SION-109 |
1.95B | 37.1% | - | 91.6% | - | 91.1% |
| MESO Mesoblast |
Biotechnology
Stem-Cell Therapy, Inflammation |
1.94B | 31.5% | - | 41.4% | - | 23.7% |
| ZBIO Zenas BioPharma |
Biotechnology
Bifunctional Monoclonal Antibody |
1.91B | 31.4% | - | 83.7% | 2.61 | 170% |
| OLMA Olema |
Biotechnology
Palazestrant, OP-3136, KAT6 |
1.82B | 33.9% | - | 61.9% | - | 133% |
| VERA Vera Therapeutics |
Biotechnology
Atacicept, Mab, Dual-Inhibitor |
1.82B | 23.4% | 3.50% | 21.1% | - | -34.2% |
| DNTH Dianthus |
Biotechnology
Monoclonal Antibody, C1s |
1.78B | 27.9% | - | 46.5% | - | 44.0% |
| JANX Janux Therapeutics |
Biotechnology
JANX007, JANX008, TRACTr, TRACIr |
1.73B | 28.6% | - | -16.3% | - | -65.5% |
| QURE Uniqure |
Biotechnology
Gene Therapy, Hemophilia B |
1.73B | 36.0% | - | 19.5% | - | 211% |
| CLDX Celldex |
Biotechnology
Monoclonal Antibody, Bispecific |
1.72B | 40.4% | - | -14.4% | - | -14.3% |
| ALVO Alvotech |
Biotechnology
Biosimilar, Autoimmune, Oncology |
1.72B | 36.6% | - | -57.8% | 24.0 | -65.5% |
| NRIX Nurix Therapeutics |
Biotechnology
BTK Degrader, IRAK4 Degrader |
1.71B | 35.8% | - | -19.3% | - | -33.4% |
| IMNM Immunome |
Biotechnology
Gamma Secretase Inhibitor |
1.71B | 45.2% | - | 57.0% | - | 6.21% |
| SNDX Syndax |
Biotechnology
Menin Inhibitor, CSF-1R Antibody |
1.66B | 36.6% | - | -8.22% | - | -1.54% |
| PHVS Pharvaris BV |
Biotechnology
Bradykinin, Antagonist |
1.61B | 24.4% | - | 74.6% | - | 10.2% |
| STOK Stoke Therapeutics |
Biotechnology
Antisense Oligonucleotides |
1.60B | 73.3% | - | 67.2% | 41.1 | 116% |
| TWST Twist Bioscience |
Biotechnology
Synthetic DNA, Gene Fragments |
1.59B | 35.7% | - | -35.2% | - | -48.3% |
| MNKD MannKind |
Biotechnology
Inhaled Insulin, Insulin Delivery |
1.56B | 64.2% | - | 0.55% | 50.7 | -25.8% |
| AGIO Agios Pharm |
Biotechnology
Mitapivat, Tebapivat, AG-181 |
1.54B | 34.6% | - | -5.33% | - | -59.9% |
| BCRX BioCryst |
Biotechnology
Antiviral Injection, Oral HAE |
1.50B | 71.6% | - | -33.2% | - | -15.1% |
| MEDCL Medincell |
Biotechnology
Schizophrenia, Postoperative Pain |
1.48B | 53.2% | - | 82.8% | - | 37.4% |
| TNGX Tango Therapeutics |
Biotechnology
PRMT5 Inhibitor, Glioblastoma |
1.40B | 33.2% | - | 38.7% | - | 127% |
| ATAI ATAI Life Sciences |
Biotechnology
Psychedelic, Serotonergic |
1.38B | 37.9% | - | 36.5% | - | 100% |
| PGEN Precigen |
Biotechnology
Gene Therapy, UltraCAR-T |
1.36B | 34.7% | - | 57.1% | - | 235% |
| DVAX Dynavax |
Biotechnology
Hepatitis Vaccine, Adjuvant |
1.34B | 38.0% | - | -30.3% | - | -27.0% |
| ORKA Oruka Therapeutics |
Biotechnology
Monoclonal Antibody |
1.34B | 28.8% | 1.0% | 48.6% | - | 16.2% |
| ARDX Ardelyx |
Biotechnology
IBS-C Therapy, Phosphate |
1.34B | 33.6% | - | 41.9% | - | -12.5% |
| BTX BlackRock |
Biotechnology
Tech, Private Equity, Mutual Fund |
1.32B | 34.0% | 87.9% | 20.9% | 51.8 | -15.6% |
| UPB Upstream Bio |
Biotechnology
Clinical-Stage, Therapeutic |
1.26B | 38.0% | - | 55.7% | - | 1.18% |
| BHVN Biohaven |
Biotechnology
Troriluzole, Taldefgrobep |
1.26B | 31.9% | - | -64.1% | - | -82.7% |
| IMTX Immatics |
Biotechnology
TCR-Engineered Cell Therapy, TCR |
1.24B | 22.0% | - | 8.04% | - | 4.02% |
| XNCR Xencor |
Biotechnology
Engineered Monoclonal Antibodies |
1.24B | 12.4% | - | -64.7% | - | -47.9% |
| KOD Kodiak Sciences |
Biotechnology
Anti-VEGF, Biopolymer Conjugate |
1.22B | 46.1% | - | 48.7% | - | 159% |
| MBX MBX Biosciences |
Biotechnology
Hypoparathyroidism, Hypoglycemia |
1.22B | 31.8% | - | 64.6% | 3.53 | 52.7% |
| PVLA Palvella |
Biotechnology
Topical Rapamycin Gel, Microcystic |
1.18B | 25.6% | - | 32.8% | - | 388% |
| ANAB AnaptysBio |
Biotechnology
Antibody, Autoimmune |
1.18B | 24.4% | - | 49.9% | - | 46.8% |
| TYRA Tyra Biosciences |
Biotechnology
Precision Medicine Platform, FGFR |
1.18B | 28.9% | - | 48.9% | - | 15.4% |
| RLAY Relay Therapeutics |
Biotechnology
PI3Ka Inhibitor, Estrogen |
1.17B | 47.4% | - | -27.1% | - | 40.3% |
| URGN UroGen Pharma |
Biotechnology
Jelmyto, UGN-102, UGN-103 |
1.16B | 48.5% | - | 66.7% | - | 65.6% |
| TSHA Taysha Gene |
Biotechnology
Gene Therapy, Rett Syndrome, CLN1 |
1.15B | 45.7% | - | 51.9% | - | 15.4% |
| CVAC CureVac |
Biotechnology
MRNA Vaccines, Oncology Therapies |
1.13B | 83.9% | - | -0.06% | 5.08 | 53.1% |
| ORIC Oric |
Biotechnology
ORIC-114, ORIC-944, ORIC-533 |
1.13B | 35.0% | - | 53.0% | - | -8.37% |
| PHARM Pharming |
Biotechnology
Recombinant C1-Inhibitor |
1.13B | 66.8% | - | 44.8% | - | 65.8% |
| OCS Oculis Holding |
Biotechnology
OCS-01, OCS-02, OCS-05 |
1.11B | 25.3% | - | 58.3% | - | 7.54% |
| CSTL Castle Biosciences |
Biotechnology
Melanoma, Squamous, Uveal |
1.11B | 53.6% | - | 24.4% | - | 8.96% |
| MNMD Mind Medicine |
Biotechnology
MM120, MM402, Anxiety, ADHD, Autism |
1.06B | 31.4% | - | 68.5% | - | 29.7% |
| NVAX Novavax |
Biotechnology
Vaccine, Adjuvant, Nanoparticle |
1.05B | 40.4% | - | -52.6% | 3.22 | -34.2% |
| ABCL Abcellera Biologics |
Biotechnology
Antibody, Metabolic, Autoimmune |
1.05B | 15.7% | - | -24.9% | - | -0.08% |
| OPK Opko Health |
Biotechnology
Diagnostics, Laboratory-Testing |
1.05B | 21.0% | - | -33.6% | - | -23.9% |
| KURA Kura Oncology |
Biotechnology
Menin Inhibitor, Farnesyl |
1.04B | 53.8% | - | -26.6% | - | -13.0% |
| GLUE Monte Rosa |
Biotechnology
MRT-2359, MRT-6160, MRT-8102, CDK2 |
1.04B | 71.3% | - | 25.3% | 50.0 | 31.9% |
| NBTX Nanobiotix |
Biotechnology
Nanoparticles, Radiotherapy |
1.01B | 49.1% | - | 76.8% | - | 471% |
| NANO Nanobiotix S.A |
Biotechnology
Nanoparticle, Radiotherapy |
1.01B | 36.1% | - | 74.4% | - | 446% |
| MDXG MiMedx |
Biotechnology
Placental Allografts, Wound Care |
1.00B | 86.1% | - | 13.5% | 25.1 | -37.3% |
| SVRA Savara |
Biotechnology
Molgramostim, Proteinosis |
1.00B | 22.1% | - | 75.5% | - | 53.8% |
| BCAX Bicara |
Biotechnology
Ficerafusp Alfa, Bifunctional |
988M | 29.8% | - | -18.6% | 3.35 | -25.0% |
| MLTX MoonLake |
Biotechnology
Nanobody, IL-17A, IL-17F |
978M | 26.9% | - | 6.04% | - | -80.3% |
| CDNA CareDx |
Biotechnology
AlloSure, AlloMap, AlloSeq |
956M | 50.3% | - | -27.2% | 14.0 | -40.5% |
| NTLA Intellia |
Biotechnology
In-Vivo CRISPR, CAR-T, NK Cell |
951M | 32.6% | - | -64.0% | - | -54.9% |
| RAPT RAPT Therapeutics |
Biotechnology
CCR4 Antagonist, Inflammation |
922M | 27.9% | - | -19.4% | - | 206% |
| IOVA Iovance |
Biotechnology
Amtagvi, Lifileucel, Proleukin |
889M | 42.7% | - | -83.1% | - | -79.4% |
| RZLT Rezolute |
Biotechnology
Antibody, Hyperinsulinism |
886M | 36.8% | - | 72.5% | - | 52.5% |
| SANA Sana Biotechnology |
Biotechnology
Allogeneic Islet Therapy, CAR-T |
876M | 35.2% | - | 12.2% | - | 21.9% |
| DAWN Day One |
Biotechnology
Tovorafenib, DAY301, VRK1 Inhibitor |
875M | 30.8% | - | -69.6% | - | -46.7% |
| GHRS GH Research |
Biotechnology
Mebufotenin, Depression |
869M | 24.6% | - | 38.0% | - | 41.6% |
| LENZ LENZ Therapeutics |
Biotechnology
Ophthalmic, Presbyopia, Clinical |
867M | 39.5% | 1.0% | 13.2% | - | -36.1% |
| CMPX Compass |
Biotechnology
Tovecimig, CTX-471, CTX-8371 |
866M | 32.6% | - | 32.8% | - | 175% |
| VIR Vir Biotechnology |
Biotechnology
HDV, RSV, HPV, Coronavirus, TCE |
851M | 28.5% | - | -79.5% | - | -39.6% |
| AVBP ArriVent |
Biotechnology
Firmonertinib, ARR-217, ARR-002 |
840M | 40.1% | - | -15.0% | - | -38.6% |
| RIGL Rigel |
Biotechnology
Kinase, Inhibitor |
839M | 92.6% | - | 69.7% | 7.47 | 43.7% |
| ABUS Arbutus Biopharma |
Biotechnology
RNAi Therapeutic, PD-L1 Inhibitor |
829M | 29.1% | - | 57.1% | - | 5.46% |
| ERAS Erasca |
Biotechnology
Naporafenib, ERAS-0015, ERAS-4001 |
828M | 34.9% | - | -48.3% | - | -21.7% |
| IVA Inventiva S.A |
Biotechnology
Lanifibranor, Odiparcil, TGF-Beta |
811M | 46.1% | - | 12.6% | - | 34.8% |
| VSTM Verastem |
Biotechnology
Avutometinib, Defactinib |
801M | 37.7% | - | 47.9% | - | 55.0% |
| ALMS Alumis |
Biotechnology
TYK2 Inhibitor, Psoriasis, Lupus |
762M | 50.9% | - | -70.3% | - | -21.6% |
| VLA Valneva SE |
Biotechnology
Japanese Encephalitis, Cholera |
751M | 20.9% | - | -6.45% | - | 83.2% |
| SPRY ARS |
Biotechnology
Epinephrine, Nasal Spray |
750M | 29.8% | - | -3.97% | - | -40.6% |
| ESPR Esperion |
Biotechnology
Cholesterol-Lowering Tablets |
730M | 55.2% | - | -25.6% | - | 3.31% |
| REPL Replimune |
Biotechnology
Oncolytic Immunotherapy, RP1, RP2 |
722M | 28.2% | - | -70.2% | - | -35.4% |
| LXEO Lexeo |
Biotechnology
Gene Therapy, Cardiomyopathy |
720M | 33.8% | - | -20.9% | - | -13.4% |
| ATXS Astria Therapeutics |
Biotechnology
Monoclonal, Antibody, Plasma |
719M | 35.6% | - | 20.8% | - | 6.32% |
| GERN Geron |
Biotechnology
Telomerase Inhibitor |
715M | 27.3% | - | -63.1% | - | -73.4% |
| ORGO Organogenesis |
Biotechnology
Wound Care, Surgical Matrix |
709M | 30.4% | - | 45.3% | - | 13.8% |
| GOSS Gossamer Bio |
Biotechnology
Seralutinib, GB002, PAH Therapy |
708M | 36.0% | - | 36.3% | - | 259% |
| CRVS Corvus |
Biotechnology
Kinase Inhibitor, Adenosine |
685M | 34.0% | - | 59.9% | - | -14.6% |
| PROK ProKidney |
Biotechnology
Cell Therapy, Renal Cells |
680M | 40.9% | - | -29.9% | - | -7.57% |
| KALV Kalvista |
Biotechnology
Plasma Kallikrein Inhibitor |
675M | 39.7% | - | 61.7% | - | 15.2% |
| PRME Prime Medicine |
Biotechnology
Gene Editing, Prime Editing |
672M | 40.6% | - | -36.2% | - | -16.3% |
| CTMX CytomX Therapeutics |
Biotechnology
Antibody-Drug Conjugate, T-Cell |
657M | 61.5% | - | 52.5% | 12.9 | 206% |
| ANNX Annexon |
Biotechnology
Antibody, Fragment |
636M | 36.7% | - | -33.1% | - | -32.6% |
| IRWD Ironwood |
Biotechnology
Linaclotide, Apraglutide, IW-3300 |
628M | 63.8% | - | -58.5% | 21.4 | -15.4% |
| FDMT 4D Molecular |
Biotechnology
Ophthalmology, Cystic-Fibrosis |
619M | 27.5% | - | -18.1% | - | 16.8% |
| MGTX MeiraGTx Holdings |
Biotechnology
Gene Therapies, Retinal Diseases |
600M | 36.3% | - | 28.1% | - | 2.13% |
| MYGN Myriad Genetics |
Biotechnology
Hereditary Cancer, Companion |
600M | 35.6% | 0.08% | -76.5% | - | -63.2% |
| RGNX Regenxbio |
Biotechnology
Gene,Therapy,AAV,Platform,Pipeline |
597M | 14.5% | - | -16.9% | - | 6.84% |
| EBS Emergent |
Biotechnology
Vaccine, Antitoxin, Auto-Injector |
596M | 50.4% | 0.14% | -13.9% | 8.46 | -3.51% |
| ASMB Assembly |
Biotechnology
Antiviral, Small-Molecule |
592M | 33.9% | - | 58.6% | - | 77.6% |
| IVVD Invivyd |
Biotechnology
Antibody, Monoclonal, Covid |
583M | 40.4% | - | 22.5% | - | 170% |